Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2022 Mar 1;41(3):230-237.
doi: 10.1097/INF.0000000000003366.

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

Rajendra P Singh  1 , Kimberly K Adkison  2 , Mark Baker  3 , Ridhi Parasrampuria  1 , Allen Wolstenholme  1 , Mark Davies  4 , Nicola Sewell  4 , Cindy Brothers  2 , Ann M Buchanan  2
Affiliations
Randomized Controlled Trial

Development of Dolutegravir Single-entity and Fixed-dose Combination Formulations for Children

Rajendra P Singh et al. Pediatr Infect Dis J. .

Abstract

Background: The World Health Organization (WHO) 2019 antiretroviral treatment guidelines recommend use of optimal treatment regimens in all populations. Dolutegravir-based regimens are the preferred first-line and second-line treatment in infants and children with HIV 4 weeks of age and above. There is an urgent need for optimal pediatric formulations of dolutegravir as single-entity (SE) and fixed-dose combination (FDC) to ensure correct dosing and adherence for swallowing and palatability. This article outlines the chronology of dolutegravir pediatric formulation development as granules and conventional and dispersible tablets in a total of 5 pharmacokinetic studies evaluating the relative bioavailability of dolutegravir SE and FDC formulations in healthy adults.

Methods: The relative bioavailability studies were 2-part, Phase I, open-label, randomized studies in healthy adults. Dolutegravir SE study compared conventional dolutegravir 50 and 25 mg with equivalent conventional 10-mg and dispersible 5-mg tablets, respectively. Subsequently, dolutegravir FDC study compared adult FDC of abacavir/dolutegravir/lamivudine and adult FDC of dolutegravir/lamivudine with their respective pediatric FDC formulations, taken as dispersion immediately or swallowed whole.

Results: As observed in previous studies, dolutegravir administered as dispersion (granules/dispersible tablets) showed relatively higher bioavailability compared with conventional tablets. The bioavailability of dolutegravir dispersible tablets (both SE and FDC) was approximately 1.6-fold higher when compared with conventional tablets. In addition, the bioavailability of abacavir/lamivudine was not impacted by dispersible formulation.

Conclusions: These studies demonstrate the successful development of pediatric dolutegravir-containing formulations as SE and FDC that permit pediatric dosing in line with WHO recommendations.

Trial registration: ClinicalTrials.gov NCT03095638 NCT03441984 NCT01302847 NCT02259127 NCT03760458.

PubMed Disclaimer

References

    1. UNAIDS. Fact sheet – World AIDS Day 2020 [UNAIDS web site]. 2020. Available from: http://unaids.mio.guru/en/resources/fact-sheet . Accessed December 2, 2020.
    1. UNICEF. Paediatric care and treatment [UNICEF web site]. 2020. Available from: https://data.unicef.org/topic/hivaids/paediatric-treatment-and-care/ . Accessed December 14, 2020.
    1. Canals F, Masiá M, Gutiérrez F. Developments in early diagnosis and therapy of HIV infection in newborns. Expert Opin Pharmacother. 2018;19:13–25.
    1. Penazzato M, Lewis L, Watkins M, et al. Shortening the decade-long gap between adult and paediatric drug formulations: a new framework based on the HIV experience in low- and middle-income countries. J Int AIDS Soc. 2018;21(suppl 1):e25049.
    1. World Health Organization. The 2018 optimal formulary and limited-use list for paediatric ARVS [WHO web site]. 2018. Available from: https://www.who.int/hiv/pub/paediatric/optimal-paediatric-arv-formulary/en/ . Accessed December 2, 2020.

Publication types

MeSH terms

Associated data